Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL447726 | 0.80 | KDR (0.44) | ROCK2GSK3BCLK4KDRFLT1 | |
| SCHEMBL446989 | 0.74 | PDE10A (0.37) | KDRPDE10AFLT1PGK1KCNH3 | |
| SCHEMBL448518 | 0.72 | KDR (0.40) | CDK2KDRPDE10AFLT1PGK1 | |
| SCHEMBL6112132 | 0.72 | MAPT (0.38) | CDK2NPSR1 | |
| SCHEMBL6227074 | 0.71 | TUBB4A (0.36) | CDK2NPSR1 | |
| SCHEMBL429466 | 0.70 | KDR (0.60) | KDRFLT1NAMPT | |
| SCHEMBL445543 | 0.70 | KDR (0.39) | CDK2KDRPDE10AHDAC4HDAC1 | |
| SCHEMBL6105148 | 0.69 | CLK4 (0.43) | CDK2CLK4NPSR1 | |
| SCHEMBL6106239 | 0.69 | KDR (0.41) | KDRNPSR1FLT1 | |
| SCHEMBL14515361 | 0.68 | KDR (0.45) | KDRNTRK1FLT1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | claimed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | claimed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311808-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1798230-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-6995162-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CDC7 2674/4885ROCK2 3564/4885MAP4K4 1929/4885 |
| US-20030125339-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | CDC7 2338/4885ROCK2 3897/4885MAP4K4 2003/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CDC7 2332/4885ROCK2 4103/4885MAP4K4 2203/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | CDC7 2674/4885ROCK2 3564/4885MAP4K4 1929/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | CDC7 2332/4885ROCK2 4103/4885MAP4K4 2203/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | CDC7 2338/4885ROCK2 3897/4885MAP4K4 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.